Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases

被引：0
|
作者：
Parth Shah
机构：
[1] ObvioHealth,
来源：
Current Cardiology Reports | 2018年 / 20卷
关键词：
Alirocumab; Evolocumab; PCSK9; Cardiovascular; Cholesterol; Lipoprotein (a);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives
    Arrieta, Alejandro
    Page, Timothy F.
    Veledar, Emir
    Nasir, Khurram
    PLOS ONE, 2017, 12 (01):
  • [32] Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
    Panagiotopoulou, Olga
    Chiesa, Scott T.
    Tousoulis, Dimitrios
    Charakida, Marietta
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (27) : 4494 - 4521
  • [33] Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors
    Safarova, Maya S.
    Kullo, Iftikhar J.
    ATHEROSCLEROSIS, 2022, 361 : 30 - 31
  • [34] Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes
    Myers, Kelly D.
    Farboodi, Niloofar
    Mwamburi, Mkaya
    Howard, William
    Staszak, David
    Gidding, Samuel
    Baum, Seth J.
    Wilemon, Katherine
    Rader, Daniel J.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2019, 12 (08):
  • [35] Safety of PCSK9 inhibitors
    Grzesk, Grzegorz
    Dorota, Bednarska
    Wolowiec, Lukasz
    Wolowiec, Anna
    Osiak, Joanna
    Kozakiewicz, Mariusz
    Banach, Joanna
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 156
  • [36] Improving prevention: risk scores, imaging, and PCSK9 inhibitors
    Luescher, Thomas F.
    EUROPEAN HEART JOURNAL, 2016, 37 (06) : 499 - 501
  • [37] PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
    Jia, Xiaoming
    Al Rifai, Mahmoud
    Saeed, Anum
    Ballantyne, Christie M.
    Virani, Salim S.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2022, 18 : 555 - 566
  • [38] Access to PCSK9 Inhibitors
    Baum, Seth J.
    Lepor, Norman E.
    Robinson, Jennifer G.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2018, 19 : S47 - S50
  • [39] Oral PCSK9 Inhibitors
    Anandita Agarwala
    Ramsha Asim
    Christie M. Ballantyne
    Current Atherosclerosis Reports, 2024, 26 : 147 - 152
  • [40] PCSK9 inhibitors are go
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (09) : 593 - 593
12345